The Intraductal Approach to Breast Cancer

Breast Cancer Research and Treatment, 2003

Breast Care, 2012

von Minckwitz: With two further negative trials and subgroup second endpoint analysis from 2 others I'm much more skeptical about using bisphosphonates now. The ABCSG study is not transferable to our current treatment strategies.

Biomedical Journal of Scientific & Technical Research, 2018

Breast cancer is the most common neoplasm among women. Worldwide, there will be about 2.1 million newly diagnosed female breast cancer cases in 2018, accounting for almost 1 in 4 cancer cases among women...

Environmental Health Perspectives, 2004

Journal of Mammary Gland Biology and Neoplasia

The first Buenos Aires Breast Cancer Symposium (BA-BCS) was held in a virtual format, between the 17 th and the 21 st of May 2021. The main goal of the meeting was to facilitate the interaction among physicians and basic researchers from South America and with peers from the rest of the world. To embrace their different interests and concerns, the congress included not only talks on basic, translational and clinical research, but also round tables to discuss diagnostic methods, research financing and biobank management, as well as virtual poster sessions in which the youngest fellows presented their recent findings. This report provides a brief overview of the talks delivered during the meeting, which addressed a wide variety of vital issues for breast cancer research mostly focused on the accurate diagnosis, prevention and treatment of this illness. The presentations included a wide spectrum of themes including hormone receptors and the relevance of their mutations, immunotherapy, cancer stem cells, mouse models, environmental hazards, genetics and epigenetics, local and systemic therapies, liquid biopsies, the metastatic cascade, therapy resistance and dormancy, among others.

2013

o r i g i n a l c o m m u n i c a t i o n INTRODUCTION B reast cancer is the second most common cancer in the United States. 1,2 In 2007, an estimated 178,480 new cases of breast cancer will be diagnosed , resulting in about 40,460 breast cancer deaths among women. 2 Based on cases diagnosed in 2000-2003, the annual age-adjusted incidence rate of breast cancer was 129.1 per 100,000 women; the age-adjusted death rate was 25.8 per 100,000 women. The median age at diagnosis of female breast cancer was 61 years, and the median age at death was 69 years. 3 During the period of 1990-2003 in Pennsylvania-the site of the study reported herein-the incidence rate was 129.3 per 100,000, and the death rate was 27.9 per 100,000. 4 The incidence rate in Pennsylvania was higher than the average rate in the country, and the death rate exceeded the Healthy People 2010 goal of 22.3 per 100,000. 5 Although the incidence of breast cancer in the United States is higher among white women than black women, the mortality rate is higher among black women. 4 Black women with invasive breast cancer have worse diseasefree and overall survival rates than do their white counterparts, even after adjusting for known prognostic factors. 6-9 Lannin et al. 10 reported that uninsured women were significantly more likely to present with late-stage breast cancer than were insured women and that this contributed to higher mortality rates. Moreover, Roetzheim et al. 11 reported that breast cancer mortality was higher among patients who had Medicaid or no health insurance than among patients who had commercial fee-for-service insurance. This difference correlated with a more advanced stage of disease at the time of diagnosis. Reasons often cited for late-stage presentation with breast cancer are related to socioeconomic, cultural and religious beliefs, the reliance on alternative therapies, the lack of knowledge about breast cancer, and the fear of an unsupportive male partner. 12 Clearly, a method of encouraging women to overcome these barriers is needed. One of the many objectives of the Centers for Healthy Hearts and Souls (CHHS), a faith-based health initiative that was founded in 1998 through a collaboration between the

2000

Surgical Oncology Clinics of North America, 2000

The overall care in the United States at that time for most women with breast cancer, although possibly the best in the world, was often fragmented and impersonal. Typically, a woman found a palpable mass in her breast and then anxiously called her family physician, internist, or gynecologist. She was usually reassured after visiting her physician a few days later. Not uncommonly, a patient like this was followed through one menstrual cycle and, if the lump persisted, she was referred for a mammogram. When she left the radiologist's office, she probably was not informed of the results. Several days might have passed before she heard from her primary physician that her mammogram was abnormal and that she needed to proceed with further evaluation. If a biopsy was indicated, she was finally referred to a surgeon, who needed to review the mammograms. This typical and inefficient scenario was anxiety producing and was the motivation for my interest in breast center development. The concept was simple: combine all of the services within a warm, supportive, efficient environment. This article describes my initial attempt at developing a breast center at UCLA, the history of the Van Nuys Breast Center (its patient population, philosophy, problems, finances, and demise), and finally, the development of the Harold E.

The Breast, 2007

The profound revolution that surgical treatment of breast cancer has undergone during the past 30 years has led to the progressive reduction of the extent of surgery, with less mutilation. As a consequence, quality of life has improved and women are now more motivated to follow screening programs for early diagnosis of the disease. Since conservative surgery is as effective as radical surgery, research is now focused on reducing radiotherapy. Overall, survival after breast cancer is not affected by reducing the extent of surgery, which, together with less invasive diagnostic procedures, has a good effect on patients' quality of life. For this reason in our Institute we are now evaluating the feasibility of a reduction of the radiation field and the sensibility and sensitivity of new diagnostic approaches for axillary staging.